Ophthalmic Drugs Conference 2018

Ophthalmic Drugs Conference is organized by SMi Group Ltd and will be held from Nov 26 - 27, 2018 at Copthorne Tara Hotel London Kensington, London, England, United Kingdom.

The target audience for this medical event is Chief, Vice Presidents, Heads, Senior Directors, Directors, Principals, Principal Scientists, Team/ Project Leaders, Clinicians, Clinical Trial Managers, Medical Officers of:
• Ophthalmology
• Ophthalmic devices
• Drug Delivery
• Drug discovery
• Research and development
• Clinical development
• Quality assurance
• Immunology, Inflammation and Allergies
• Market Access

Course Description:
As the global population ages, the incidence of ophthalmic disorders continues to grow, and thus the interest of pharmaceutical and biotech companies is increasingly focused towards innovation of novel approaches for the development of ophthalmic drugs, driving the growth of the global ophthalmic drug market, which is projected to reach £30 billion by 2023.

Benefits Of Attending:
Building on last year's success, this must-attend conference will bring together industry experts to discuss and analyse the latest advancements and challenges within ophthalmic drug development and delivery. Some notable areas of interest have been neuroprotection in ophthalmology, advancements in gene therapy, AMD clinical trial updates, and novel approaches for delivery of ocular drugs. The two-day event will also feature two interactive workshops on the 28th November 2018, led by twoXAR and Aston University

Course Sessions:
• Discover recent advances in the treatment of glaucoma
• Gain insight into the first FDA-approved gene therapy, developed for the treatment of inherited retinal dystrophy
• Discuss case studies on novel non-invasive and site-specific drug delivery strategies
• Examine the applications of artificial intelligence in drug discovery
• Explore use of biomarkers and surrogate end-points from a regulatory perspective

Additional details will be posted as soon as they are available.